−2.99USD
−154.94 MUSD
43.95 MUSD
43.67 M
About Merus N.V.
Sector
Industry
CEO
Sven Ante Lundberg
Website
Headquarters
Utrecht
Founded
2003
ISIN
NL0011606264
FIGI
BBG00B8LXMS5
Merus NV is a clinical-stage immuno-oncology company, which engages in the discovery and development of bispecific antibody therapeutics. Its pipeline includes Biclonics for solid and hematological tumors. The company was founded by Ton Logtenberg and Hennie Hoogenboom on June 16, 2003 and is headquartered in Utrecht, the Netherlands.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of MRUS is 39.80 USD — it has decreased by 1.66% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Merus N.V. stocks are traded under the ticker MRUS.
Merus N.V. is going to release the next earnings report on May 6, 2024. Keep track of upcoming events with our Earnings Calendar.
MRUS stock is 7.36% volatile and has beta coefficient of 2.28. Check out the list of the most volatile stocks — is Merus N.V. there?
One year price forecast for Merus N.V. has a max estimate of 69.00 USD and a min estimate of 52.00 USD.
MRUS earnings for the last quarter are −0.43 USD per share, whereas the estimation was −0.76 USD resulting in a 43.27% surprise. The estimated earnings for the next quarter are −0.78 USD per share. See more details about Merus N.V. earnings.
Merus N.V. revenue for the last quarter amounts to 11.03 M USD despite the estimated figure of 9.92 M USD. In the next quarter revenue is expected to reach 9.60 M USD.
Yes, you can track Merus N.V. financials in yearly and quarterly reports right on TradingView.
MRUS stock has fallen by 6.53% compared to the previous week, the month change is a 10.86% fall, over the last year Merus N.V. has showed a 88.63% increase.
MRUS net income for the last quarter is −60.15 M USD, while the quarter before that showed −23.01 M USD of net income which accounts for −161.40% change. Track more Merus N.V. financial stats to get the full picture.
Today Merus N.V. has the market capitalization of 2.34 B, it has decreased by 2.63% over the last week.
No, MRUS doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, MRUS shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Merus N.V. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Merus N.V. technincal analysis shows the sell today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Merus N.V. stock shows the buy signal. See more of Merus N.V. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on Merus N.V. future price: according to them, MRUS price has a max estimate of 69.00 USD and a min estimate of 52.00 USD. Read a more detailed Merus N.V. forecast: see what analysts think of Merus N.V. and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Merus N.V. EBITDA is −154.01 M USD, and current EBITDA margin is −350.44%. See more stats in Merus N.V. financial statements.